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Introduction
During myocardial ischemia, coronary blood flow interruption deprives
cardiomyocytes of oxygen, glucose and fatty acids. Ischemic damage is
exacerbated by a burst of reactive oxygen species (ROS) generated at
reperfusion when oxygen interacts with damaged mitochondrial electron
transport chains (ETC), especially uncoupled complexes I and III (Fig. 1,2).
Nicotinamide adenine dinucleotide phosphate oxidase (Nox) activity can also
release ROS, inducing additional tissue/organ damage1,2,3.

Figure 1. Electrons leaking from complexes I Figure 2. Decreasing mitochondrial ROS production
and III are accepted by oxygen (O2) to generate prevents destructive effects, including loss of
superoxide (O2-). Adapted from Szeto 2006.
membrane integrity. Modified from Szeto 2006.

Surgical intervention or thrombolytic treatments can restore coronary blood
flow. However, as blood flow reestablishes, oxidative stress leads to I/R injury.
Clinical treatment remains a challenge as no pharmaceutical agents effectively
limit I/R-induced damage. Mitochondria are implicated in I/R as a major
source of ROS3,4,5. Excess ROS leads to mitochondrial and cardiac contractile
dysfunction6. Conventional antioxidants have limited efficacy in myocardial
I/R because they are not targeted selectively to where most I/R damage occurs,
in mitochondria (Fig. 3)3,4,5. Mitoquinone (mitoQ, MW=600 g/mol), a
coenzyme Q analog, easily crosses phospholipid bilayers and is driven by the
large electrochemical membrane potential to concentrate mitoQ several
hundred-fold within mitochondria. The respiratory chain reduces mitoQ to its
active ubiquinol antioxidant form to limit myocardial I/R injury5. The SS-31
(Szeto-Schiller) peptide ((D-Arg)-Dmt-Lys-Phe-Amide, MW=640 g/mol,
Genemed Synthesis, Inc., San Antonio, TX) is also of interest since it is cellpermeable, specifically targeted to inner mitochondrial membranes based on
its alternating cationic aromatic residue sequence, with an antioxidant
dimethyltyrosine moeity. SS peptides scavenge ROS in I/R models4.
Figure 3. Mitochondrial ROS stimulate ROS
production outside mitochondria, increasing
oxidative stress and apoptosis signaling cascade
activation. ETC complexes and Nox4 are major
ROS sources in dysfunctional mitochondria.
Specific mitochondrial-targeted antioxidants
exert cardioprotective effects. Adapted from
Bayeva et al. 2013 and modified.

(1,000 U) injection intraperitoneally (i.p.). Each heart was
rapidly excised and subjected to retrograde perfusion via
the aorta, while immersed in a 160 mL water-jacketed
reservoir, with a modified Krebs’ buffer (in mmol/L: 17.0
dextrose, 120.0 NaCl, 25.0 NaHCO3, 2.5 CaCl2, 0.5
EDTA, 5.9 KCl and 1.2 MgCl2). The perfusate was
maintained at 37oC, kept at 80 mmHg constant pressure,
aerated with 95% O2-5% CO2 and equilibrated at a pH of
7.35-7.45. A side arm in the perfusion line was used for the
infusion of 5 mL of autologous plasma with or without
mitoQ (4, 40, 80 μM) or SS-31 (25, 50, 100 μM). A flow
meter (T106, Transonic Systems, Inc., Ithaca, NY)
monitored coronary flow. Left ventricular end-systolic
pressure (LVESP), left ventricular end-diastolic pressure
(LVEDP), heart rate and the peak rates of rise and fall in
the first derivative of left ventricular pressure (dP/dtmax and
dP/dtmin, respectively) were monitored using a pressure
transducer (SPR-524, Millar Instruments, Inc., Houston,
TX) positioned in the left ventricular cavity and recorded
using a Powerlab Station acquisition system (AD
Instruments, Grand Junction, CO). Left ventricular
developed pressure (LVDP) was calculated by subtracting Figure 2.
LVEDP from LVESP. Cardiac function parameters were Myocardial I/R apparatus.
measured every 5 min for 15 min to obtain stable baseline measurements.
Ischemia was induced for 30 min by stopping Krebs’ buffer flow. After
ischemia, Krebs’ buffer flow was restored while infusing 5 mL of plasma with
or without mitoQ or SS-31 at a rate of 1 mL/min for 5 min. Cardiac function
parameters were recorded every 5 min for 45 min. Three left ventricle sections
from apex to middle were used in 1% 2,3,5- triphenyltetrazolium chloride
(TTC) staining for 20 min at 37oC to detect infarct size. Frozen sections (8
µm) of the left ventricle base were subjected to dihydroethidium (DHE)
staining for 2 min at 22oC to fluoroscopically detect SO release. Fluorescence
intensity is expressed in arbitrary units quantified by Image J.
Statistical Analysis
All data in the text and figures are presented as means ± SEM. The cardiac
function and TTC staining data were analyzed by ANOVA using post hoc
analysis with the Student-Newman-Keuls test. Probability values of <0.05
were considered statistically significant.

Results

Figure 6. Weight ratios of infarcted to at risk cardiac tissue in I/R as determined by TTC staining.
Treatment with mitoQ (40, 80 μM) or SS-31 (25, 50, 100 μM) at reperfusion significantly reduced
infarct size compared to untreated I/R hearts (**P<0.01).

Figure 7. Representative photographs of left ventricular tissue from control (A), 4 μM mitoQ (B), 40
μM mitoQ (C), 80 μM mitoQ (D) I/R hearts subjected to DHE staining at 40x magnification by
fluorescence microscopy. I/R hearts treated with mitoQ (40, 80 μM) expressed less SO release than
untreated I/R hearts, suggesting mitoQ attenuates SO release in myocardial I/R.

Conclusions
The data suggest that inhibiting mitochondrial derived ROS with selective
mitochondrial-targeted antioxidants, such as mitoQ and SS-31, can attenuate
myocardial I/R injury by reducing ROS formation to limit cardiac contractile
dysfunction and infarct size. Additionally, the data suggest that agents such
as mitoQ and SS-31 can work expeditiously and effectively when
administered at the time of coronary blood flow restoration. Therefore,
treatment with mitoQ or SS-31 may be useful in the clinical setting in cases
of myocardial infarction, where pretreatment is not always a practical option.

Although mitochondrial-targeted antioxidant pretreatment can effectively limit
I/R injury, pretreatment is not always possible in cases of myocardial
infarction. Therefore, evaluating cardioprotective efficacy of mitochondrialtargeted antioxidants when given at reperfusion is of high significance.

Hypothesis
We hypothesized that antioxidants specifically targeted to the mitochondria
will attenuate myocardial I/R injury by limiting cardiac contractile
dysfunction, cardiac tissue damage and SO release in isolated perfused rat
hearts subjected to I/R compared to untreated I/R hearts.
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